These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9610435)

  • 1. Treatment of fibrinous effusion.
    Starck T
    J Cataract Refract Surg; 1998 May; 24(5):575. PubMed ID: 9610435
    [No Abstract]   [Full Text] [Related]  

  • 2. Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery.
    Wedrich A; Menapace R; Ries E; Polzer I
    J Cataract Refract Surg; 1997; 23(6):873-7. PubMed ID: 9292671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolysis of postcataract fibrin membranes in children.
    Leung AT; Lam DS; Rao SK
    J Cataract Refract Surg; 2000 Jan; 26(1):4; author reply 5. PubMed ID: 10646130
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of recombinant tissue plasminogen activator for intracameral fibrinolysis following cataract surgery.
    Wedrich A; Menapace R; Mühlbauer-Ries E
    Int Ophthalmol; 1994-1995; 18(5):277-80. PubMed ID: 7607808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of total hyphema with relatively low-dose tissue plasminogen activator.
    Kim MH; Koo TH; Sah WJ; Chung SM
    Ophthalmic Surg Lasers; 1998 Sep; 29(9):762-6. PubMed ID: 9760614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolysis of postcataract fibrin membranes in children.
    Mehta JS; Adams GG
    J Cataract Refract Surg; 2000 Jan; 26(1):4-5. PubMed ID: 10646131
    [No Abstract]   [Full Text] [Related]  

  • 7. Intraocular recombinant tissue-plasminogen activator fibrinolysis of fibrin formation after cataract surgery in children.
    Klais CM; Hattenbach LO; Steinkamp GW; Zubcov AA; Kohnen T
    J Cataract Refract Surg; 1999 Mar; 25(3):357-62. PubMed ID: 10079440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose intraocular tissue plasminogen activator treatment for traumatic total hyphema, postcataract, and penetrating keratoplasty fibrinous membranes.
    Starck T; Hopp L; Held KS; Marouf LM; Yee RW
    J Cataract Refract Surg; 1995 Mar; 21(2):219-24. PubMed ID: 7791066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tissue plasminogen activator in treatment of fibrinous membranes after cataract surgery].
    Oficjalska-Młyńczak J; Marek J; Zajac-Pytrus H; Nizankowska MH; Koziorowska M
    Klin Oczna; 1996; 98(6):423-5. PubMed ID: 9340414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracameral tissue plasminogen activator after glaucoma surgery. Indications, effectiveness, and complications.
    Lundy DC; Sidoti P; Winarko T; Minckler D; Heuer DK
    Ophthalmology; 1996 Feb; 103(2):274-82. PubMed ID: 8594514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracameral tissue plasminogen activator: management of a fibrin clot occluding a Molteno tube.
    Pastor SA; Schumann SP; Starita RJ; Fellman RL
    Ophthalmic Surg; 1993 Dec; 24(12):853-4. PubMed ID: 8115104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of tissue plasminogen activator in post-traumatic total hyphaema.
    Laatikainen L; Mattila J
    Graefes Arch Clin Exp Ophthalmol; 1996 Jan; 234(1):67-8. PubMed ID: 8750854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue plasminogen activator for the treatment of postoperative intraocular fibrinous membranes following cataract surgery.
    Schmitz K; Greite JH; Bartenschlager EM
    Ger J Ophthalmol; 1995 Mar; 4(2):75-9. PubMed ID: 7795512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracameral injection of tissue plasminogen activator to treat severe postoperative fibrinous reaction in iridocorneal endothelial syndrome.
    Hong BK; Francis BA
    Digit J Ophthalmol; 2013; 19(2):21-3. PubMed ID: 24109245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of anterior segment fibrinous reactions and hemorrhage with intracameral low dose rt-PA: clinical study and review of the literature].
    Le Rouic JF; Behar-Cohen F; Nghiem MH; Renard G; Chauvaud D
    J Fr Ophtalmol; 2000 Dec; 23(10):977-83. PubMed ID: 11139689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of postcataract fibrinous membranes with tissue plasminogen activator.
    Moon J; Chung S; Myong Y; Chung S; Park C; Baek N; Rhee S
    Ophthalmology; 1992 Aug; 99(8):1256-9. PubMed ID: 1513579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue plasminogen activator in the management of anterior chamber fibrin formation.
    Erol N
    J Cataract Refract Surg; 2004 Nov; 30(11):2254-5; author reply 2255. PubMed ID: 15519061
    [No Abstract]   [Full Text] [Related]  

  • 18. Tissue plasminogen activator for preserving inferior peripheral iridectomy patency in eyes with silicone oil.
    MacCumber MW; McCuen BW; Toth CA; Ferrone PJ; Jaffe GJ
    Ophthalmology; 1996 Feb; 103(2):269-73. PubMed ID: 8594513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose tissue plasminogen activator.
    Osher RH
    J Cataract Refract Surg; 2003 Dec; 29(12):2258; author reply 2258-9. PubMed ID: 14709279
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy].
    Zhao P; Wang W
    Zhonghua Yan Ke Za Zhi; 1995 Jul; 31(4):255-8. PubMed ID: 8745515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.